City Therapeutics, Inc. (CTY) Financial Statements

4 Followers

City Therapeutics, Inc. Financial Overview

City Therapeutics, Inc.'s market cap is currently $1.05B. The company's EPS TTM is ; its P/E ratio is ―; City Therapeutics, Inc. is scheduled to report earnings on ―, and the estimated EPS forecast is ―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 19	Dec 18	Dec 17
Income Statement
Total Revenue	$ 8.16B	$ 8.49B	$ 8.55B
Gross Profit	$ 5.72B	$ 5.73B	$ 5.67B
Operating Income	$ 2.88B	$ 2.66B	$ 2.31B
EBITDA	$ 3.83B	$ 4.04B	$ 3.84B
Net Income	$ 1.83B	$ 1.67B	$ 1.66B
Balance Sheet
Cash & Short-Term Investments	$ 2.00M	$ 5.00M	$ 1.00M
Total Assets	$ 21.00B	$ 20.58B	$ 20.87B
Total Debt	$ 5.95B	$ 5.96B	$ 7.28B
Net Debt	$ 5.95B	$ 5.95B	$ 7.28B
Total Liabilities	$ 10.88B	$ 10.71B	$ 11.53B
Stockholders' Equity	$ 10.12B	$ 9.87B	$ 9.34B
Cash Flow
Free Cash Flow	$ 2.28B	$ 2.75B	$ 1.11B
Operating Cash Flow	$ 3.33B	$ 3.79B	$ 2.44B
Investing Cash Flow	$ -1.72B	$ -1.15B	$ -1.44B
Financing Cash Flow	$ -1.61B	$ -2.63B	$ -1.00B

Currency in USD

City Therapeutics, Inc. Earnings and Revenue History

Income Statement >

City Therapeutics, Inc. Debt to Assets

Balance Sheet >

City Therapeutics, Inc. Cash Flow

Cash Flow >

City Therapeutics, Inc. Forecast EPS vs Actual EPS

Currently, no data available

Please return soon. This page is being updated.

Earnings >